Fennec Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $6,974 | $7,260 | $25,263 | $10,004 |
Gross Profit | 5,617 | 6,652 | 24,716 | 9,300 |
EBITDA | -5,202 | -5,037 | 13,681 | -1,868 |
EBIT | -5,063 | 12,958 | -1,938 | |
Net Income | -5,735 | -5,551 | 12,837 | -2,756 |
Net Change In Cash | 6,974 | 7,260 | 25,263 | 10,004 |
Free Cash Flow | -2,377 | -8,040 | 38,872 | -4,974 |
Cash | 40,320 | 43,047 | 51,131 | 13,201 |
Basic Shares | 27,371 | 27,297 | 31,091 | 26,833 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $21,641 | $1,535 | $170 | $170 |
Gross Profit | 20,359 | 1,449 | 0 | 170 |
EBITDA | -13,005 | -22,543 | -17,185 | -17,985 |
EBIT | -13,292 | -22,692 | -34,408 | -18,387 |
Net Income | -16,339 | -24,839 | -17,456 | -17,922 |
Net Change In Cash | 21,641 | 1,535 | 170 | 170 |
Cost of Revenue | -9,244 | 16,694 | ||
Free Cash Flow | -17,457 | -18,058 | -14,222 | -15,595 |
Cash | 13,201 | 23,774 | 21,100 | 30,344 |
Basic Shares | 26,574 | 26,275 | 26,006 | 23,704 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.21 |
2024-06-30 | -$0.20 |
2024-03-31 | $0.47 |
2023-12-31 | -$0.10 |
